000007518 001__ 7518
000007518 005__ 20240926125520.0
000007518 0247_ $$2DOI$$a10.6083/n583xv58g
000007518 037__ $$aETD
000007518 041__ $$aeng
000007518 245__ $$aDevelopment of novel nanoparticle based PLK1, EGFR, and PD-L1 targeted therapies for lung cancer
000007518 260__ $$bOregon Health and Science University
000007518 269__ $$a2019
000007518 336__ $$aDissertation
000007518 502__ $$bPh.D.
000007518 502__ $$gBiomedical Engineering
000007518 520__ $$aNon-small cell lung cancer (NSCLC) is the deadliest form of cancer and represents nearly a fourth of all cancer related deaths worldwide. Identifying molecular targets and developing effective therapeutic regimens to improve NSCLC treatments and patient quality of life is needed. Nanoparticles possess unique properties to enhance treatment efficacy and reduce toxic side effects of traditional therapies. In my dissertation, I exploited versatile mesoporous silica nanoparticles (MSNP) to improve radiation therapy and immunotherapy, which are two key treatments for NSCLC patients.
000007518 540__ $$fCC BY
000007518 542__ $$fIn copyright - single owner
000007518 650__ $$aRadiation$$025066
000007518 650__ $$aImmunotherapy$$020724
000007518 650__ $$aNanoparticles$$037592
000007518 650__ $$aNanotechnology$$034718
000007518 6531_ $$acancer
000007518 6531_ $$alung cancers
000007518 691__ $$aSchool of Medicine$$041369
000007518 692__ $$aDepartment of Biomedical Engineering$$041397
000007518 7001_ $$aReda, Moataz$$uOregon Health and Science University$$041354
000007518 7201_ $$aYantasee, Wassana$$uOregon Health and Science University$$eAdvisor$$7Personal
000007518 8564_ $$97e772b49-afc5-4d32-b9e5-1265edcbe7f9$$s2809239$$uhttps://digitalcollections.ohsu.edu/record/7518/files/reda.moataz.2019.pdf
000007518 905__ $$a/rest/prod/n5/83/xv/58/n583xv58g
000007518 909CO $$ooai:digitalcollections.ohsu.edu:7518$$pstudent-work
000007518 980__ $$aTheses and Dissertations